{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T05:54:40Z","timestamp":1767851680355,"version":"3.49.0"},"reference-count":130,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"vor","delay-in-days":366,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","valueinhealthjournal.com","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1016\/j.jval.2015.08.010","type":"journal-article","created":{"date-parts":[[2015,10,24]],"date-time":"2015-10-24T21:17:42Z","timestamp":1445721462000},"page":"956-968","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["Cost-Effectiveness Analysis of Universal Human Papillomavirus Vaccination Using a Dynamic Bayesian Methodology: The BEST II Study"],"prefix":"10.1016","volume":"18","author":[{"given":"Katrin","family":"Haeussler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Marcellusi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco Saverio","family":"Mennini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giampiero","family":"Favato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mauro","family":"Picardo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgia","family":"Garganese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Bononi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvano","family":"Costa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Scambia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Zweifel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Capone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianluca","family":"Baio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jval.2015.08.010_bib1","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1086\/505982","article-title":"Genital human papillomavirus infection","volume":"43","author":"Dunne","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jval.2015.08.010_bib2","doi-asserted-by":"crossref","first-page":"A38","DOI":"10.1016\/j.jval.2013.03.219","article-title":"Loss of health utilities due to HPV-induced diseases in men and women: a multicenter Italian study","volume":"16","author":"Mennini","year":"2013","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2015.08.010_bib3","article-title":"Colorectal Cancer Screening Options Appraisal: Cost-Effectiveness, Cost-Utility and Resource Impact of Alternative Screening Options for Colorectal Cancer","author":"Tappenden","year":"2004","journal-title":"Report to the English Bowel Cancer Screening Working Group"},{"key":"10.1016\/j.jval.2015.08.010_bib4","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1002\/lary.21412","article-title":"The cost-effectiveness of community-based screening for oral cancer in high-risk males in the United States: a Markov decision analysis approach","volume":"121","author":"Dedhia","year":"2011","journal-title":"Laryngoscope"},{"issue":"Suppl. 5","key":"10.1016\/j.jval.2015.08.010_bib5","doi-asserted-by":"crossref","first-page":"v128","DOI":"10.1093\/annonc\/mdg756","article-title":"EUROCARE-3 summary: cancer survival in Europe at the end of the 20th century","volume":"14","author":"Coleman","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jval.2015.08.010_bib6","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ejogrb.2003.11.026","article-title":"Gynaecological cancers in Umbria (Italy): trends of incidence, mortality and survival, 1978\u20131998","volume":"115","author":"Minelli","year":"2004","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.jval.2015.08.010_bib7","unstructured":"Boyle P, Levin B. World Cancer Report 2008. World Health Organization and International Agency for Research on Cancer. Lyon, France: International Agency for Research on Cancer, 2008. Available from: http:\/\/www.iarc.fr\/en\/publications\/pdfs-online\/wcr\/2008\/wcr_2008.pdf. [Accessed August 12, 2015]."},{"key":"10.1016\/j.jval.2015.08.010_bib8","doi-asserted-by":"crossref","first-page":"8352","DOI":"10.1016\/j.vaccine.2007.09.027","article-title":"HPV vaccine efficacy in preventing persistent cervical HPV infection: a systematic review and meta-analysis","volume":"25","author":"La Torre","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.jval.2015.08.010_bib9","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1016\/j.vaccine.2013.10.081","article-title":"HPV vaccines to prevent cervical cancer and genital warts: an update","volume":"32","author":"Dochez","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.jval.2015.08.010_bib10","doi-asserted-by":"crossref","first-page":"a769","DOI":"10.1136\/bmj.a769","article-title":"Economic evaluation of human papillomavirus vaccination in the United Kingdom","volume":"337","author":"Jit","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.jval.2015.08.010_bib11","doi-asserted-by":"crossref","first-page":"b3884","DOI":"10.1136\/bmj.b3884","article-title":"Cost-effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States","volume":"339","author":"Kim","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.jval.2015.08.010_bib12","doi-asserted-by":"crossref","first-page":"6858","DOI":"10.1016\/j.vaccine.2010.08.030","article-title":"Impact of vaccinating boys and men against HPV in the United States","volume":"28","author":"Elbasha","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.jval.2015.08.010_bib13","doi-asserted-by":"crossref","first-page":"3732","DOI":"10.1016\/j.vaccine.2014.05.007","article-title":"Mind the gaps: what\u2019s missing from current economic evaluations of universal HPV vaccination?","volume":"32","author":"Marsh","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.jval.2015.08.010_bib14","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.4161\/hv.25754","article-title":"A critical review of cost-effectiveness analyses of vaccinating males against human papillomavirus","volume":"9","author":"Jiang","year":"2013","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.jval.2015.08.010_bib15","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1177\/0272989X02239651","article-title":"Economic evaluation of vaccination programs: the impact of herd-immunity","volume":"23","author":"Brisson","year":"2003","journal-title":"Med Decis Making"},{"key":"10.1016\/j.jval.2015.08.010_bib16","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1136\/sextrans-2011-050306","article-title":"Epidemiology of, and behavioural risk factors for, sexually transmitted human papillomavirus infection in men and women in Britain","volume":"88","author":"Johnson","year":"2012","journal-title":"Sex Transm Infect"},{"key":"10.1016\/j.jval.2015.08.010_bib17","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1016\/S0140-6736(13)61947-9","article-title":"Prevalence, risk factors, and uptake of interventions for sexually transmitted infections in Britain: findings from the National Surveys of Sexual Attitudes and Lifestyles (NATSAL)","volume":"382","author":"Sonnenberg","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jval.2015.08.010_bib18","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jegh.2013.11.003","article-title":"Prevalence and risk factors of human papillomavirus infection types 16\/18\/45 in a cohort of French females aged 15\u201323 years","volume":"4","author":"Baudu","year":"2014","journal-title":"J Epidemiol Glob Health"},{"key":"10.1016\/j.jval.2015.08.010_bib19","unstructured":"Danish Centre for Health Technology Assessment (DACEHTA). Reduction in the risk of cervical cancer by vaccination against human papillomavirus (HPV) \u2013 a health technology assessment. Health Technol Assess 2007;9. Available from: http:\/\/www.sst.dk\/publ\/Publ2007\/MTV\/HPV\/HPV_ vaccination_en.pdf. [Accessed August 12, 2015]."},{"key":"10.1016\/j.jval.2015.08.010_bib20","first-page":"1322","article-title":"The value of including boys in an HPV vaccination programme: a cost-effectiveness analysis in a low-resource setting","volume":"97","author":"Kim","year":"2007","journal-title":"BMJ"},{"key":"10.1016\/j.jval.2015.08.010_bib21","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1017\/S0266462310000085","article-title":"Human papillomavirus transmission and cost-effectiveness of introducing quadrivalent HPV vaccination in Denmark","volume":"26","author":"Olsen","year":"2010","journal-title":"Int J Technol Assess Health Care"},{"key":"10.1016\/j.jval.2015.08.010_bib22","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.mbs.2011.02.009","article-title":"The role of optimal control in assessing the most cost-effective implementation of a vaccination programme: HPV as a case study","volume":"231","author":"Brown","year":"2011","journal-title":"Math Biosci"},{"key":"10.1016\/j.jval.2015.08.010_bib23","doi-asserted-by":"crossref","first-page":"8443","DOI":"10.1016\/j.vaccine.2011.07.096","article-title":"The cost- effectiveness of male HPV vaccination in the United States","volume":"29","author":"Chesson","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.jval.2015.08.010_bib24","doi-asserted-by":"crossref","first-page":"3687","DOI":"10.1002\/sim.1586","article-title":"Bayesian approaches to multiple sources of evidence and uncertainty in complex cost-effectiveness modelling","volume":"22","author":"Spiegelhalter","year":"2003","journal-title":"Stat Med"},{"key":"10.1016\/j.jval.2015.08.010_bib25","article-title":"Bayesian Methods in Health Economics","author":"Baio","year":"2013","journal-title":"Chapman & Hall, CRC Biostatistics Series, Boca Raton, FL, USA"},{"key":"10.1016\/j.jval.2015.08.010_bib26","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1097\/MLR.0b013e318269e06d","article-title":"Bayesian modelling to assess the effectiveness of a vaccination strategy to prevent HPV-related diseases: the BEST study","volume":"50","author":"Favato","year":"2012","journal-title":"Med Care"},{"key":"10.1016\/j.jval.2015.08.010_bib27","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1002\/ijc.29143","article-title":"Age-stratified 5-year risks of cervical precancer among women with enrollment and newly detected HPV infection","volume":"136","author":"Gage","year":"2014","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jval.2015.08.010_bib28","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1186\/1471-2334-13-238","article-title":"Difference in overall and age-specific prevalence of high-risk human papillomavirus infection in Italy: evidence from NTCC trial","volume":"13","author":"Baussano","year":"2013","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jval.2015.08.010_bib29","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1155\/2007\/136906","article-title":"HPV infections in adolescents","volume":"23","author":"Moscicki","year":"2007","journal-title":"Disease Markers"},{"key":"10.1016\/j.jval.2015.08.010_bib30","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1136\/jcp.55.4.244","article-title":"The causal relation between human papillomavirus and cervical cancer","volume":"55","author":"Bosch","year":"2002","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.jval.2015.08.010_bib31","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1093\/oxfordjournals.jncimonographs.a003477","article-title":"Chapter 3: cofactors in human papillomavirus carcinogenesis\u2014role of parity, oral contraceptives, and tobacco smoking","volume":"31","author":"Castellsagu\u00e9","year":"2003","journal-title":"J Natl Cancer Inst Monogr"},{"key":"10.1016\/j.jval.2015.08.010_bib32","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1093\/jnci\/94.21.1604","article-title":"Herpes simplex virus-2 as a human papillomavirus cofactor in the etiology of invasive cervical cancer","volume":"94","author":"Smith","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jval.2015.08.010_bib33","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/ijc.20257","article-title":"Chlamydia trachomatis and invasive cervical cancer: a pooled analysis of the IARC multicentric case-control study","volume":"111","author":"Smith","year":"2004","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jval.2015.08.010_bib34","doi-asserted-by":"crossref","unstructured":"Gelman A, Carlin JB, Stern HS, et al. Bayesian Data Analysis (2nd ed.). Chapman&Hall\/CRC, Boca Raton, FL, USA, 2004","DOI":"10.1201\/9780429258480"},{"key":"10.1016\/j.jval.2015.08.010_bib35","unstructured":"The Italian Office for National Statistics (ISTAT). Access all data. Population and households. Mortality. 2011 census. Available from: http:\/\/www.istat.it. [Accessed August 12, 2015]."},{"key":"10.1016\/j.jval.2015.08.010_bib36","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1093\/oxfordjournals.aje.a010166","article-title":"Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis","volume":"151","author":"Myers","year":"2000","journal-title":"Am J Epidemiol"},{"issue":"Suppl. 3","key":"10.1016\/j.jval.2015.08.010_bib37","article-title":"Chapter 5: updating the natural history of HPV and anogenital cancer","volume":"24","author":"Moscicki","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.jval.2015.08.010_bib38","unstructured":"ISTAT. La Prevenzione dei Tumori Femminili in Italia; il Ricorso a Pap Test e Mammografia: anni 2004-2005, 2006. Available from: http:\/\/www.istat.it\/salastampa\/comunicati\/non_calendario\/20061204_00\/testointegrale.pdf. [Accessed August 12, 2015]."},{"issue":"Suppl. 3","key":"10.1016\/j.jval.2015.08.010_bib39","first-page":"27","article-title":"Activity level and process indicators of organised programmes for cervical cancer screening in Italy","volume":"30","author":"Ronco","year":"2006","journal-title":"Epidemiol Prev"},{"key":"10.1016\/j.jval.2015.08.010_bib40","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1472-6963-6-36","article-title":"Estimation of Pap-test coverage in an area with an organised screening program: challenges for survey methods","volume":"6","author":"Giorgi Rossi","year":"2006","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.jval.2015.08.010_bib41","unstructured":"ISTAT. I determinant del ricorso allo screening dei tumori femminili. Informazione statistica e politiche per la promozione della salute \u2013 atti del convegno di roma, 2002. Available from: http:\/\/www.istat.it\/dati\/catalogo\/20041201_01\/Atti_del_convegno_salute.pdf. [Accessed August 12, 2015]."},{"key":"10.1016\/j.jval.2015.08.010_bib42","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1093\/jnci\/dji115","article-title":"Cervical cancer in women with comprehensive health care access: attributable factors in the screening process","volume":"97","author":"Leyden","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jval.2015.08.010_bib43","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1016\/S0140-6736(07)60852-6","article-title":"Effect of prophylactic human papillomavirus L1 virus-like particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials","volume":"369","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.jval.2015.08.010_bib44","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1056\/NEJMoa061760","article-title":"Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases","volume":"356","year":"2007","journal-title":"N Engl J Med"},{"issue":"Suppl. 2","key":"10.1016\/j.jval.2015.08.010_bib45","first-page":"S25","article-title":"Revisione sistematica e meta-analisi dei trial clinici sull\u2019efficacia del vaccino quadrivalente anti-HPV. Report HTA del vaccino quadrivalente anti-HPV Gardasil","volume":"6","author":"La Torre","year":"2009","journal-title":"Italian JPH"},{"key":"10.1016\/j.jval.2015.08.010_bib46","first-page":"69","article-title":"CDC grand rounds: reducing the burden of HPV associated cancer and disease","volume":"63","author":"Dunne","year":"2014","journal-title":"MMWR"},{"key":"10.1016\/j.jval.2015.08.010_bib47","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.3201\/eid1011.040222","article-title":"Evaluating human papillomavirus vaccination programs","volume":"10","author":"Taira","year":"2004","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.jval.2015.08.010_bib48","unstructured":"Cancer Research UK. Anal cancer incidence statistics. Available from: http:\/\/www.cancerresearchuk.org\/sites\/default\/files\/cstream-node\/cases_rates_anus.pdf. [Accessed August 12, 2015]."},{"key":"10.1016\/j.jval.2015.08.010_bib49","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1093\/aje\/kwg067","article-title":"Cancer in a population-based cohort of men and women in registered homosexual partnerships","volume":"157","author":"Frisch","year":"2003","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.jval.2015.08.010_bib50","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/1471-2458-9-71","article-title":"Epidemiology and costs of cervical cancer screening and cervical dysplasia in Italy","volume":"9","author":"Giorgi Rossi","year":"2009","journal-title":"BMC Public Health"},{"key":"10.1016\/j.jval.2015.08.010_bib51","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.ejca.2004.07.005","article-title":"Prevalence of human papillomavirus infection in women in Turin, Italy","volume":"41","author":"Ronco","year":"2005","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jval.2015.08.010_bib52","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S1470-2045(06)70731-8","article-title":"Human papillomavirus testing and liquid-based cytology in primary screening of women younger than 35 years: results at recruitment for a randomised controlled trial","volume":"7","author":"Ronco","year":"2006","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jval.2015.08.010_bib53","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/sj.bjc.6602002","article-title":"The predicted effect of changes in cervical screening practice in the UK: results from a modelling study","volume":"91","author":"Canfell","year":"2004","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jval.2015.08.010_bib54","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/1471-2334-5-77","article-title":"Prevalence of human papillomavirus cervical infection in an Italian asymptomatic population","volume":"5","author":"Centurioni","year":"2005","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jval.2015.08.010_bib55","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3310\/hta14530","article-title":"Cost-effectiveness of screening high risk HIV-positive men who have sex with men (MSM) and HIV-positive women for anal cancer","volume":"14","author":"Czoski-Murray","year":"2010","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.jval.2015.08.010_bib56","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1097\/00002030-199511000-00007","article-title":"Prospective study of high grade anal squamous intraepithelial neoplasia in a cohort of homosexual men: influence of HIV infection, immunosuppression and human papillomavirus infection","volume":"9","author":"Critchlow","year":"1995","journal-title":"AIDS"},{"key":"10.1016\/j.jval.2015.08.010_bib57","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1056\/NEJMoa061760","article-title":"Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases","volume":"356","author":"Garland","year":"2007","journal-title":"N Engl J Med"},{"issue":"Suppl. 2A","key":"10.1016\/j.jval.2015.08.010_bib58","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1016\/j.urology.2010.04.007","article-title":"Penile cancer\u2014prevention and premalignant conditions","volume":"76","author":"Minhas","year":"2010","journal-title":"Urology"},{"key":"10.1016\/j.jval.2015.08.010_bib59","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1053\/joms.2003.50056","article-title":"Is detection of oral and oropharyngeal squamous cancer by a dental health care provider associated with a lower stage at diagnosis?","volume":"61","author":"Holmes","year":"2003","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.jval.2015.08.010_bib60","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1002\/hed.20270","article-title":"Oral and pharyngeal cancer: analysis of patient delay at different tumor stages","volume":"27","author":"Brouha","year":"2005","journal-title":"Head Neck"},{"key":"10.1016\/j.jval.2015.08.010_bib61","doi-asserted-by":"crossref","first-page":"200","DOI":"10.2471\/BLT.08.053231","article-title":"Cost-effectiveness of oral cancer screening: results from a cluster randomized controlled trial in India","volume":"87","author":"Subramanian","year":"2009","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.jval.2015.08.010_bib62","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.joms.2009.03.056","article-title":"Survival and patterns of relapse in patients with oral tongue cancer","volume":"68","author":"Rusthoven","year":"2010","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.jval.2015.08.010_bib63","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1097\/IGC.0b013e318249bce6","article-title":"Trends in treatment and survival of late-stage squamous cell vulvar carcinomas: analysis of the Surveillance, Epidemiology, and End Results (SEER) database","volume":"22","author":"Ramanah","year":"2012","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.jval.2015.08.010_bib64","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1016\/j.ejca.2012.01.030","article-title":"Successful centralisation of patients with vulvar carcinoma: a population-based study in The Netherlands","volume":"48","author":"van den Einden","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jval.2015.08.010_bib65","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1002\/1097-0142(19820515)49:10<2185::AID-CNCR2820491034>3.0.CO;2-M","article-title":"Carcinoma of the penis: analysis of 219 cases","volume":"49","author":"Narayana","year":"1982","journal-title":"Cancer"},{"key":"10.1016\/j.jval.2015.08.010_bib66","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.radonc.2011.09.015","article-title":"Node-negative T1-T2 anal cancer: radiotherapy alone or concomitant chemoradiotherapy?","volume":"102","author":"Zilli","year":"2012","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.jval.2015.08.010_bib67","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/1471-2407-11-55","article-title":"Concurrent cisplatin, continuous infusion fluorouracil and radiotherapy followed by tailored consolidation treatment in nonmetastatic anal squamous cell carcinoma","volume":"11","author":"Zampino","year":"2011","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jval.2015.08.010_bib68","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1002\/1097-0142(20011215)92:12<3012::AID-CNCR10131>3.0.CO;2-E","article-title":"Nasal and paranasal sinus carcinoma: are we making progress? A series of 220 patients and a systematic review","volume":"92","author":"Dulguerov","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.jval.2015.08.010_bib69","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.ygyno.2011.12.449","article-title":"Human papillomavirus as a favorable prognostic biomarker in squamous cell carcinomas of the vagina","volume":"125","author":"Alonso","year":"2012","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.jval.2015.08.010_bib70","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.ygyno.2012.06.005","article-title":"Impact of the new FIGO 2009 staging classification for vulvar cancer on prognosis and stage distribution","volume":"127","author":"Tabbaa","year":"2012","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.jval.2015.08.010_bib71","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.urology.2011.12.048","article-title":"Clinical and pathologic factors of prognostic significance in penile squamous cell carcinoma in a North American population","volume":"79","author":"Bethune","year":"2012","journal-title":"Urology"},{"key":"10.1016\/j.jval.2015.08.010_bib72","doi-asserted-by":"crossref","first-page":"e000736","DOI":"10.1136\/bmjopen-2011-000736","article-title":"Governance of preventive health intervention and on time verification of its efficiency: the GIOVE study","volume":"2","author":"Mennini","year":"2012","journal-title":"BMJ Open"},{"key":"10.1016\/j.jval.2015.08.010_bib73","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.1185\/030079907X242610","article-title":"Cost of varicella-related hospitalizations in an Italian paediatric hospital: comparison with possible vaccination expenses","volume":"23","author":"Azzari","year":"2007","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jval.2015.08.010_bib74","doi-asserted-by":"crossref","first-page":"839","DOI":"10.2165\/00019053-200422130-00003","article-title":"Varicella vaccination in Italy: an economic evaluation of different scenarios","volume":"22","author":"Coudeville","year":"2004","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jval.2015.08.010_bib75","unstructured":"Ministero della Salute. Nomenclatore Tariffario. Prestazioni di Assistenza Specialistica Ambulatoriale. Available from: http:\/\/www.salute.gov.it\/portale\/temi\/p2_6.jsp?id=1767&area=programmazioneSanitariaLea&menu=lea.[ Accessed August 12, 2015]."},{"key":"10.1016\/j.jval.2015.08.010_bib76","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/LGT.0b013e31823cde2f","article-title":"A cost-effectiveness analysis of anal cancer screening in HIV-positive women","volume":"16","author":"Lazenby","year":"2012","journal-title":"J Low Genit Tract Dis"},{"key":"10.1016\/j.jval.2015.08.010_bib77","unstructured":"Nomenclatore Tariffario Regionale 2006. Regione Lazio. Aggiornamento del Nomenclatore Tariffario Regionale delle Prestazioni Specialistiche Ambulatoriali. Modificazioni ed Integrazioni alla DGR no. 439 del 21\/07\/2006. Available from: http:\/\/www.regione.lazio.it\/binary\/rl_main\/tbl_delibere\/71366.doc. [Accessed August 12, 2015]."},{"key":"10.1016\/j.jval.2015.08.010_bib78","unstructured":"Nomenclatore Tariffario Regionale 2006 (versione secondo la classi_cazione ICD-IX). Regione Emilia-Romagna. Available from: http:\/\/salute.regione.emilia-romagna.it\/documentazione\/leggi\/regionali\/delibere\/delibere-specialistica.[ Accessed August 12, 2015]."},{"key":"10.1016\/j.jval.2015.08.010_bib79","unstructured":"Costa S., Favato G. Evaluation of the economic impact produced by the prevention of events induced by the HPV 6-11 virus types contained in the quadrivalent vaccine. Available from: http:\/\/www.ssrn.com\/abstract=1080113. [Accessed August 12, 2015]."},{"key":"10.1016\/j.jval.2015.08.010_bib80","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.ygyno.2010.06.025","article-title":"Hospital costs incurred by the Italian National Health Service for invasive cervical cancer","volume":"119","author":"Ferrandina","year":"2010","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.jval.2015.08.010_bib81","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.1185\/03007990802485694","article-title":"Treatment patterns and associated costs for genital warts in Italy","volume":"24","author":"Merito","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jval.2015.08.010_bib82","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/S0002-9343(00)00349-1","article-title":"Cost-effectiveness of screening for anal squamous intraepithelial lesions and anal cancer in human immunodeficiency virus-negative homosexual and bisexual men","volume":"108","author":"Goldie","year":"2000","journal-title":"Am J Med"},{"key":"10.1016\/j.jval.2015.08.010_bib83","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1371\/journal.pone.0049699","article-title":"Economic burden of human papillomavirus-related diseases in Italy","volume":"7","author":"Baio","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jval.2015.08.010_bib84","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1136\/gut.2006.095109","article-title":"Option appraisal of population-based colorectal cancer screening programmes in England","volume":"56","author":"Tappenden","year":"2007","journal-title":"Gut"},{"key":"10.1016\/j.jval.2015.08.010_bib85","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1097\/MOO.0b013e3282f5520a","article-title":"Modern methods to predict costs for the treatment and management of head and neck cancer patients: examples of methods used in the current literature","volume":"16","author":"Wineland","year":"2008","journal-title":"Curr Opin Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.jval.2015.08.010_bib86","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1186\/1471-2407-11-475","article-title":"A cost-effectiveness analysis of a preventive exercise program for patients with advanced head and neck cancer treated with concomitant chemo-radiotherapy","volume":"11","author":"Ret\u00e8l","year":"2011","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jval.2015.08.010_bib87","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/1471-2334-11-73","article-title":"Economic burden of vulvar and vaginal intraepithelial neoplasia: retrospective cost study at a German dysplasia centre","volume":"11","author":"Hampl","year":"2011","journal-title":"BMC Inf Dis"},{"key":"10.1016\/j.jval.2015.08.010_bib88","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1158\/1055-9965.EPI-09-0067","article-title":"Human papillomavirus infections and vulvar disease development","volume":"18","author":"Garland","year":"2009","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.jval.2015.08.010_bib89","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1046\/j.1365-2133.2003.54013.x","article-title":"Epidemiology and health services research. Treating Bowen\u2019s disease: a cost-minimization study","volume":"148","author":"Ramrakha-Jones","year":"2003","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jval.2015.08.010_bib90","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/S0022-5347(05)00399-X","article-title":"Cost analysis of neonatal circumcision in a large health maintenance organization","volume":"175","author":"Schoen","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.jval.2015.08.010_bib91","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1177\/0272989X04271039","article-title":"A cost-utility analysis of neonatal circumcision","volume":"24","author":"van Howe","year":"2004","journal-title":"Med Decis Making"},{"key":"10.1016\/j.jval.2015.08.010_bib92","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1093\/pubmed\/fdn045","article-title":"Cost-utility analysis of screening high-risk groups for anal cancer","volume":"30","author":"Karnon","year":"2008","journal-title":"J Public Health"},{"key":"10.1016\/j.jval.2015.08.010_bib93","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1136\/sextrans-2011-050161","article-title":"Quality of life valuations of HPV-associated cancer health states by the general population","volume":"88","author":"Conway","year":"2012","journal-title":"Sex Transm Infect"},{"key":"10.1016\/j.jval.2015.08.010_bib94","doi-asserted-by":"crossref","first-page":"5845","DOI":"10.1016\/j.vaccine.2014.07.099","article-title":"Comparing the cost-effectiveness of two- and three-dose schedules of human papillomavirus vaccination: a transmission-dynamic modelling study","volume":"32","author":"Laprise","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.jval.2015.08.010_bib95","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1086\/522864","article-title":"Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection","volume":"196","year":"2007","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jval.2015.08.010_bib96","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1086\/597307","article-title":"The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic non-vaccine HPV types in generally HPV-naive women aged 16-26 years","volume":"199","author":"Brown","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jval.2015.08.010_bib97","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1086\/597309","article-title":"The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic non-vaccine HPV types in sexually active women aged 16-26 years","volume":"199","author":"Wheeler","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jval.2015.08.010_bib98","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa021641","article-title":"Epidemiologic classification of human papillomavirus types associated with cervical cancer","volume":"348","author":"Mu\u00f1oz","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jval.2015.08.010_bib99","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S1473-3099(12)70187-1","article-title":"Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis","volume":"12","author":"Malag\u00f3n","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jval.2015.08.010_bib100","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1002\/sim.5590","article-title":"Adaptive Markov chain Monte Carlo forward projection for statistical analysis in epidemic modelling of human papillomavirus","volume":"32","author":"Korostil","year":"2013","journal-title":"Stat Med"},{"key":"10.1016\/j.jval.2015.08.010_bib101","series-title":"An Introduction to Infectious Disease Modelling","author":"Vynnycky","year":"2010"},{"key":"10.1016\/j.jval.2015.08.010_bib102","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1086\/507432","article-title":"Prevalence of HPV infection among men: a systematic review of the literature","volume":"194","author":"Dunne","year":"2006","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jval.2015.08.010_bib103","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1093\/infdis\/jir644","article-title":"Genital transmission of human papillomavirus in recently formed heterosexual couples","volume":"204","author":"Burchell","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jval.2015.08.010_bib104","doi-asserted-by":"crossref","first-page":"5473","DOI":"10.1016\/j.vaccine.2010.05.056","article-title":"Understanding differences in predictions of HPV vaccine effectiveness: a comparative model-based analysis","volume":"28","author":"Van de Velde","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.jval.2015.08.010_bib105","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/hec.804","article-title":"Comprehensive decision analytical modelling in economic evaluation: a Bayesian approach","volume":"13","author":"Cooper","year":"2004","journal-title":"Health Econ"},{"key":"10.1016\/j.jval.2015.08.010_bib106","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1097\/AOG.0b013e3181ea1834","article-title":"Anal intraepithelial neoplasia in women with genital intraepithelial neoplasia","volume":"116","author":"Santoso","year":"2010","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.jval.2015.08.010_bib107","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.clinthera.2014.11.002","article-title":"Health utilities loss with HPV-induced diseases in men and women: the HPV Italian Collaborative Study Group","volume":"37","author":"Marcellusi","year":"2015","journal-title":"Clin Ther"},{"key":"10.1016\/j.jval.2015.08.010_bib108","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/LGT.0b013e31823cde2f","article-title":"A cost-effectiveness analysis of anal cancer screening in HIV-positive women","volume":"16","author":"Bratton Lazenby","year":"2012","journal-title":"J Low Genit Tract Dis"},{"key":"10.1016\/j.jval.2015.08.010_bib109","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1136\/jech.55.2.123","article-title":"The discount rate in the economic evaluation of prevention: a thought experiment","volume":"55","author":"Bonneux","year":"2001","journal-title":"J Epidemiol Community Health"},{"key":"10.1016\/j.jval.2015.08.010_bib110","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1177\/009286150103500122","article-title":"Guidelines for economic evaluations in Italy: recommendations from the Italian group of pharmacoeconomic studies","volume":"35","author":"Capri","year":"2001","journal-title":"Drug Inform J"},{"key":"10.1016\/j.jval.2015.08.010_bib111","unstructured":"National Institute for Clinical Excellence. Guide to the Methods of Technology Appraisal. London: National Institute for Clinical Excellence, 2013. Available from: http:\/\/www.nice.org.uk\/article\/pmg9\/chapter\/foreword. [Accessed August 12, 2015]."},{"key":"10.1016\/j.jval.2015.08.010_bib112","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.jval.2012.01.005","article-title":"On discounting of health gains from human papillomavirus vaccination: effects of different approaches","volume":"15","author":"Westra","year":"2012","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2015.08.010_bib113","first-page":"91","article-title":"AIES (Associazione Italiana di Economia Sanitaria). Proposta di linee guida per la valutazione economica degli interventi sanitari","volume":"10","author":"Aguzzi","year":"2009","journal-title":"Politiche sanitarie"},{"issue":"Suppl. 1","key":"10.1016\/j.jval.2015.08.010_bib114","doi-asserted-by":"crossref","first-page":"A54","DOI":"10.1016\/j.vaccine.2009.02.052","article-title":"Anti-HPV vaccination: a review of recent economic data for Italy","volume":"27","author":"Mennini","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.jval.2015.08.010_bib115","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1136\/bmj.329.7459.224","article-title":"National Institute for Clinical Excellence and its value judgements","volume":"329","author":"Rawlins","year":"2004","journal-title":"BMJ"},{"key":"10.1016\/j.jval.2015.08.010_bib116","unstructured":"Centers for Disease Control and Prevention. Human papillomavirus (HPV): HPV and men (fact sheet). Available from: http:\/\/www.cdc.gov\/std\/hpv\/stdfact-hpv-and-men.htm. [Accessed August 12, 2015]."},{"key":"10.1016\/j.jval.2015.08.010_bib117","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.jval.2012.06.011","article-title":"Dynamic transmission modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-5","volume":"15","author":"Pitman","year":"2012","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2015.08.010_bib118","first-page":"239","article-title":"A comparison of three methods for selecting values of input variables in the analysis of output from a computer code","volume":"21","author":"McKay","year":"1979","journal-title":"Technometrics"},{"key":"10.1016\/j.jval.2015.08.010_bib119","series-title":"Bayesian Approaches to Clinical Trials and Health-Care Evaluation","author":"Spiegelhalter","year":"2004"},{"key":"10.1016\/j.jval.2015.08.010_bib120","series-title":"Decision Modelling for Health Economic Evaluation","author":"Briggs","year":"2006"},{"key":"10.1016\/j.jval.2015.08.010_bib121","unstructured":"Package BCEA. Bayesian cost-effectiveness analysis. Available from: http:\/\/cran.r-project.org\/web\/packages\/BCEA\/BCEA.pdf. [Accessed August 12, 2015]."},{"key":"10.1016\/j.jval.2015.08.010_bib122","unstructured":"SAVI. Sheffield Accelerated Value of Information. Available from: http:\/\/savi.shef.ac.uk\/SAVI\/. [Accessed August 12, 2015]."},{"key":"10.1016\/j.jval.2015.08.010_bib123","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3201\/eid1301.060438","article-title":"Model for assessing human papillomavirus vaccination strategies","volume":"13","author":"Elbasha","year":"2007","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.jval.2015.08.010_bib124","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.vaccine.2007.10.056","article-title":"Cost-effectiveness of quadrivalent human papillomavirus (HPV) vaccination in Mexico: a transmission dynamic model-based evaluation","volume":"26","author":"Insinga","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.jval.2015.08.010_bib125","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1007\/s11538-008-9338-x","article-title":"A multi-type HPV transmission model","volume":"70","author":"Elbasha","year":"2008","journal-title":"Bull Math Biol"},{"key":"10.1016\/j.jval.2015.08.010_bib126","doi-asserted-by":"crossref","first-page":"4091","DOI":"10.1016\/j.vaccine.2009.09.125","article-title":"Transmission dynamic modelling of the impact of human papillomavirus vaccination in the United Kingdom","volume":"28","author":"Choi","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.jval.2015.08.010_bib127","doi-asserted-by":"crossref","first-page":"5133","DOI":"10.1016\/j.vaccine.2009.06.039","article-title":"Cost-effectiveness analysis of human papillomavirus vaccination programs to prevent cervical cancer in Austria","volume":"27","author":"Zechmeister","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.jval.2015.08.010_bib128","series-title":"Vaccines for the 21st Century: A Tool for Decision Making","author":"Stratton","year":"2000"},{"key":"10.1016\/j.jval.2015.08.010_bib129","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1097\/00001648-200211000-00006","article-title":"The theoretical population-level impact of a prophylactic human papilloma virus vaccine","volume":"13","author":"Hughes","year":"2002","journal-title":"Epidemiology"},{"key":"10.1016\/j.jval.2015.08.010_bib130","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1586\/14760584.2014.963561","article-title":"The next generation of HPV vaccines: nonavalent vaccine V503 on the horizon","volume":"13","author":"Chatterjee","year":"2014","journal-title":"Expert Rev Vaccines"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301515020471?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301515020471?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T06:01:31Z","timestamp":1599717691000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301515020471"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":130,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["S1098301515020471"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2015.08.010","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-Effectiveness Analysis of Universal Human Papillomavirus Vaccination Using a Dynamic Bayesian Methodology: The BEST II Study","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2015.08.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}